Melt doses first subject in Phase III trial of non-opioid sedation tablet [Yahoo! Finance]
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: Yahoo! Finance
A sublingual tablet, MELT-300 combines midazolam and ketamine, aiming to provide a new sedation alternative. The randomised, double-blind, three-arm study is designed to assess the product's safety and efficacy. In the trial, 528 subjects will be randomised into a 4:1:1 ratio to receive either MELT-300, sublingual midazolam, and sublingual placebo for procedural sedation before undergoing cataract surgery at 14 clinical sites. Melt anticipates reporting the topline results from the trial in the fourth quarter of this year. MELT-300 utilises Catalent's Zydis technology to rapidly dissolve the tablet, allowing for absorption through the sublingual mucosa. The subject dosing in Phase III follows positive outcomes from the Phase II clinical trial of MELT-300 against sublingual placebo, sublingual midazolam, and sublingual ketamine in more than 300 patients. MELT-300 demonstrated statistical superiority in providing procedural sedation compared to each of the comparator arms i
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- Sarepta cut to Neutral at Citi on risks to valuation [Seeking Alpha]Seeking Alpha
- Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies [Yahoo! Finance]Yahoo! Finance
- Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy [Seeking Alpha]Seeking Alpha
- Novo Nordisk plots $4.1 billion in U.S. factory amid Ozempic shortage, the same day it pulled out of its Ireland development project [Fortune]Fortune
- Catalent, Inc. (NYSE: CTLT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
CTLT
Earnings
- 2/9/24 - Miss
CTLT
Sec Filings
- 6/5/24 - Form 4
- 6/4/24 - Form 144
- 5/29/24 - Form 8-K
- CTLT's page on the SEC website